Author

Lisa M. Rooper

Johns Hopkins UniversityORCID 0000-0001-5636-9753Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Farhoud FarajiiD· 2 shared Gary L. GalliaiD· 2 shared Kenny VuiD· 2 shared Nyall R. LondoniD· 2 shared Sreenivasulu Gunti· 2 shared Andrew P. LaneiD· 1 shared Anirudh SaraswathulaiD· 1 shared Anjali Nandal· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Farhoud FarajiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedJun 11, 2025

Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma

Fernando Tadeu Zamunér, Sreenivasulu Gunti, Gabriel J. Starrett…·Nyall R. London

This study identifies molecular differences between HPV-associated and HPV-independent SNSCC, showing HPV drives tumorigenesis and suggesting YAP/TAZ and PI3K inhibition as therapeutic targets.

11 citationstop 2%

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 19, 2025

In vivo CRISPR screening identifies NF1/RASA1/TP53 co-mutations and downstream MEK signaling as a common key mechanism of sinonasal tumorigenesis

Kenny Vu, Sreenivasulu Gunti, Ramya Viswanathan…·Nyall R. London

This study identifies NF1/RASA1/TP53 co-mutations and MEK signaling as key drivers of sinonasal tumorigenesis through in vivo CRISPR screening and drug response testing.

DOI 10.1101/2025.05.19.654661

mousegenetic perturbation / CRISPR

𝕏 PostBluesky